Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Invested Capital (2016 - 2025)

Historic Invested Capital for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $39.3 million.

  • Immucell's Invested Capital rose 502.38% to $39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.3 million, marking a year-over-year increase of 502.38%. This contributed to the annual value of $38.1 million for FY2024, which is 284.94% up from last year.
  • Immucell's Invested Capital amounted to $39.3 million in Q3 2025, which was up 502.38% from $39.7 million recorded in Q2 2025.
  • Immucell's Invested Capital's 5-year high stood at $39.7 million during Q2 2025, with a 5-year trough of $27.9 million in Q2 2023.
  • Its 5-year average for Invested Capital is $34.6 million, with a median of $34.1 million in 2022.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 1662.32% in 2023, then soared by 2460.51% in 2024.
  • Quarter analysis of 5 years shows Immucell's Invested Capital stood at $33.4 million in 2021, then dropped by 5.9% to $31.4 million in 2022, then rose by 18.04% to $37.1 million in 2023, then grew by 2.85% to $38.1 million in 2024, then increased by 3.01% to $39.3 million in 2025.
  • Its Invested Capital stands at $39.3 million for Q3 2025, versus $39.7 million for Q2 2025 and $39.2 million for Q1 2025.